Navigation Links
Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 2017
Date:12/3/2012

SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) today announced its intention to offer, subject to market and other conditions, $350 million principal amount of convertible senior notes due December 1, 2017 in an offering registered under the Securities Act of 1933, as amended. Prior to August 7, 2017, the notes will be convertible only upon certain circumstances and during certain periods. Upon conversion, holders will receive up to the principal amount of the notes in cash and any excess conversion value in shares of Volcano's common stock. Volcano also expects to grant the underwriters of the offering an option to purchase up to $52.5 million aggregate principal amount of additional notes to cover over-allotments.

The notes will be general senior unsecured obligations of Volcano and will pay interest semi-annually. The interest rate, conversion rate, offering price and other terms will be determined at the time of pricing of the offering. Volcano expects to use a portion of the net proceeds of the offering of the notes to pay the costs of the convertible note hedge transactions described below, taking into account the proceeds of the warrant transactions described below, and may use up to approximately $50.0 million of the net proceeds from the offering to fund repurchases of its outstanding 2.875% Convertible Senior Notes due 2015 (the "2015 Notes"). Volcano may also use a portion of the net proceeds to invest in or acquire complementary products, businesses or technologies.  The remaining net proceeds are intended for working capital and general corporate purposes.

In connection with any repurchases of Volcano's outstanding 2015 Notes, Volcano expects to terminate the convertible note hedge transactions and warrant transactions it entered into at the time of the offering of the 2015 Notes in an amount corresponding to the portion of
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
2. Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast
3. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
6. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
7. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
8. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
9. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
10. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
11. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
(Date:10/22/2014)... Oct. 22, 2014 Moms are ready to ... for themselves and their kids, according to the results ... & Fitness Go Mobile for Moms, the latest installment ... the number 1 pregnancy and parenting web and mobile ... percent of moms surveyed say they can,t think of ...
(Date:10/22/2014)... ATLANTA , Oct. 22, 2014  CryoLife, Inc. ... and tissue processing company focused on cardiac and vascular ... , President and Chief Executive Officer, has been elected ... 2014. Steven G. Anderson , Executive ... Pat has proven to be an excellent leader who ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... NovaCardia, Inc.,today presented preliminary results from a pilot ... antagonist in development for the,treatment of patients with ... trend toward efficacy for the 30 milligram,dose. Patients ... in dyspnea, or shortness of breath, which is ...
... - Geron,Corporation (Nasdaq:GERN) today announced the presentation ... human,embryonic stem cell (hESC)-based therapeutic for the ... attack by the human immune,system., Presented by ... of,Clinical Immunology Societies meeting in San Diego, ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... of abuse by intimate partners have significantly higher health ... of such abuse, according to a study conducted at ... higher costs and utilization continued long after the abuse ... of Washington (UW), and the Harborview Injury Prevention and ...
... how some passengers describe it.// , They ... were infected with a stomach flu-causing bug; norovirus aboard the ... This virus causes a contagious gastric illness, gastroenteritis that leaves ... , The liner’s owner Cunard Line notified the ...
... that neurologists believe will help in the management of epilepsy. ... New York carried out a study that showed that some ... occur. The findings were published in Neurology, the scientific journal ... Haut. ,Haut's team studied 71 adult patients ...
... and Forests has called for an action plan and ... National Workshop// on ‘Human - Leopard Conflict Management’ here ... need to have a re-look at our existing strategies ... one of the challenging issues facing wildlife managers in ...
... Parliament's health committee is all set to tighten the ... ,Three days of public hearing starting on Jan 23, ... organizations will make submissions before the committee. ... and the sponsorship of sports and other popular events ...
... (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important ... diabetics in the// December 22, 2006, Journal of ... time help researchers to identify potential targets for ... fully eliminate, the body's overproduction of glucose. ...
Cached Medicine News:Health News:Health Care Costs - Significant for Abused Women 2Health News:When Epilepsy Patients Play Soothsayers 2Health News:VBI Provides Potential Targets to Diabetes Therapeutics 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: